AGP27 Antibody

Shipped with Ice Packs
In Stock

Description

Alpha-1 Acid Glycoprotein (AGP) Antibody Interactions

AGP (orosomucoid) is an immunomodulatory acute-phase protein with demonstrated antibody-mediated functions:

Key Findings from Preclinical Studies

ParameterAnti-CD27 m1 IsotypeAnti-CD27 m2a IsotypeSource
Tumor Growth Inhibition73%42%
Survival Extension39 days (median)27 days
FcγR Binding ProfilePrefers FcγRIIbBinds FcγRI/IV

Epitope mapping reveals membrane-distal binding confers stronger agonism (EC50 0.8 nM vs 12.4 nM for proximal epitopes) . Clinical-grade varlilumab shows enhanced efficacy when Fc-engineered for IIb receptor clustering .

Antibody Characterization Methodologies

Critical quality assessments for research antibodies include:

Validation Metrics for GAPDH Antibody (A00227-1)

ApplicationDilutionSample Types ValidatedValidation Image ConfirmedSource
Western Blot0.1-0.5μg/mlHuman, rat, mouse tissues36 kDa band across species
IHC2-5μg/mlHuman carcinoma tissuesDAB staining in 3 cancer types
Flow Cytometry1-3μg/10⁶ cellsFixed Hela cellsClear histogram separation

Multi-platform validation reduces risks of non-specific binding observed in 12% of commercial antibodies .

Emerging Antibody Development Strategies

Recent advances addressing antibody reproducibility crises:

ApproachImpact FactorExample OutcomesSource
Recombinant Engineering40% higher specificity vs polyclonalsYCharOS KO validation pipeline
AI-Driven Design5x faster epitope predictionDe novo antibody generation
Fc Domain Optimization2.3x enhanced tumor penetrationm1 isotype engineering

The Only Good Antibodies (OGA) initiative removed 20% of non-functional commercial antibodies through open validation .

While "AGP27 Antibody" remains uncharacterized in current literature, these adjacent findings demonstrate rigorous antibody validation requirements and therapeutic engineering principles applicable to novel antibody development. Researchers proposing AGP27 studies should implement:

  1. Epitope mapping via hydrogen-deuterium exchange mass spectrometry

  2. FcγR binding profiling using surface plasmon resonance

  3. Cross-species reactivity testing in KO models

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
AGP27 antibody; At3g06360 antibody; F24P17.17Classical arabinogalactan protein 27 antibody
Target Names
AGP27
Uniprot No.

Target Background

Function
AGP27 Antibody targets a proteoglycan that plays a multifaceted role in development. This includes processes like differentiation, cell-cell communication, embryogenesis, and programmed cell death.
Database Links

KEGG: ath:AT3G06360

STRING: 3702.AT3G06360.1

UniGene: At.40535

Protein Families
Classical AGP family
Subcellular Location
Cell membrane; Lipid-anchor, GPI-anchor.

Q&A

Given the lack of specific information on "AGP27 Antibody" in the search results, I will create a collection of FAQs that are relevant to antibody research in general, focusing on aspects that could apply to any antibody, including hypothetical or emerging antibodies like AGP27. These FAQs will cover both basic and advanced research questions, emphasizing experimental design and data analysis.

What is the role of antibodies in research?

Antibodies are crucial tools in research for their ability to specifically recognize and bind to antigens, making them invaluable for diagnostics, therapeutics, and basic scientific studies. They can be used to detect proteins, modulate immune responses, or deliver drugs to specific targets .

How are antibodies typically produced for research?

Antibodies are produced through various methods, including hybridoma technology, phage display, and recombinant DNA technology. These methods allow researchers to generate antibodies with high specificity and affinity for their target antigens .

How do researchers design experiments to evaluate antibody efficacy?

To evaluate antibody efficacy, researchers often use in vitro and in vivo models. In vitro studies involve cell cultures to assess binding affinity and functional effects, while in vivo studies use animal models to evaluate therapeutic potential and safety .

What are common challenges in antibody development, and how are they addressed?

Common challenges include achieving optimal binding affinity and specificity, overcoming immune tolerance, and ensuring stability and safety. These challenges are addressed through epitope mapping, Fc engineering, and rigorous preclinical testing .

How do researchers analyze data from antibody binding studies?

Data analysis involves quantifying binding affinity using techniques like ELISA or surface plasmon resonance (SPR). Statistical methods are used to compare binding kinetics and assess the significance of differences between experimental groups .

What tools are used for structural analysis of antibody-antigen complexes?

Structural analysis often employs techniques such as X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy (Cryo-EM). These methods provide detailed insights into the molecular interactions between antibodies and their antigens .

How can computational methods enhance antibody design?

Computational tools, including machine learning and molecular modeling, are increasingly used to predict antibody-antigen interactions and design optimized antibodies with improved affinity and specificity. These methods leverage large datasets of known antibody structures to guide rational design .

What role does epitope mapping play in optimizing antibody function?

Epitope mapping is crucial for understanding how antibodies interact with antigens. By identifying the specific regions of the antigen that an antibody binds to, researchers can engineer antibodies with enhanced agonistic or antagonistic properties, improving their therapeutic potential .

How might emerging technologies like single-cell sequencing impact antibody research?

Technologies like single-cell sequencing and proteomics can provide detailed insights into the antibody response at the cellular level, enabling researchers to identify rare, highly effective antibodies and understand their development and function more precisely .

What are the implications of broadly neutralizing antibodies for infectious diseases?

Broadly neutralizing antibodies, like those against COVID-19 variants, offer potential for universal treatments or vaccines. They can protect against multiple strains of a virus, providing a powerful tool in the fight against rapidly evolving pathogens .

Data Table Example: Antibody Binding Affinity

AntibodyAntigenBinding Affinity (KD)Method
SC27Spike Protein10^-9 MSPR
AGP27Hypothetical TargetN/AN/A

Note: The table is hypothetical for AGP27, as specific data is not available.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.